JATT III Acquisition Corp IPO Pricing
Analysis based on 11 articles · First reported Aug 25, 2026 · Last updated Aug 26, 2026
The IPO provides BHAV Acquisition Corp with $60 million in gross proceeds to fund a future business combination, adding to the pipeline of healthcare-focused SPACs in the market. Investor interest in biotech and life sciences SPACs may be positively influenced by this offering, though the impact is limited given the company's early stage and lack of a target.
BHAV Acquisition Corp, a newly formed special purpose acquisition company (SPAC) incorporated in the United Kingdom — Cayman Islands, priced its initial public offering of 6,000,000 ordinary shares at $10.00 per share, raising $60 million in gross proceeds. The shares are expected to begin trading on the Nasdaq Capital Market Capital Market under the ticker symbol 'JTTT' on August 26, 2026, with the offering expected to close on August 27, 2026. Guggenheim Partners, LLC is acting as sole book-running manager, and the company has granted underwriters a 45-day option to purchase up to 900,000 additional shares to cover over-allotments. The registration statement was declared effective by the United States — United States Securities and Exchange Commission on August 25, 2026. The company has not yet identified a business combination target but intends to focus on healthcare and life sciences, particularly biotechnology and data-driven approaches such as machine learning and computational biology. The SPAC is sponsored by JATT Ventures III L.P. and led by CEO and Chairman Dr. Someit Sidhu, CFO Nicholas Fernandez, and board members Verender S. Badial, Arjun Goyal, Jonathon Kluft, and Christopher Staral.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard